A clinical trial performed with GSK256073, a synthetic agonist of GPR109A, in T2DM patients found an improvement in glucose homeostasis and insulin sensitivity after treatment with this drug [66]. This evidence concerns the gene HCAR2 and type 2 diabetes mellitus.